Orphazyme A/S ADR (ORPH): Price and Financial Metrics
ORPH Price/Volume Stats
| Current price | $0.87 | 52-week high | $77.77 |
| Prev. close | $0.89 | 52-week low | $0.51 |
| Day low | $0.85 | Volume | 941,400 |
| Day high | $0.96 | Avg. volume | 1,371,185 |
| 50-day MA | $1.51 | Dividend yield | N/A |
| 200-day MA | $3.77 | Market Cap | 30.72M |
ORPH Stock Price Chart Interactive Chart >
Orphazyme A/S ADR (ORPH) Company Bio
Orphazyme A/S engages in development of treatment for patients living with life-threatening and debilitating rare diseases. It provides Arimoclomol program and molecular entities program. The company was founded by Anders Mørkeberg Hinsby, Marja Jäättela, Martin Rahbek Kornum, and Thomas Kirkegaard Jensen in 2009 and is headquartered in Copenhagen, Denmark.
Latest ORPH News From Around the Web
Below are the latest news stories about Orphazyme A that investors may wish to consider to help them evaluate ORPH as an investment opportunity.
Orphazyme announces update on regulatory review of arimoclomol in the European UnionOrphazyme A/SCompany announcementNo. 07/2022Inside informationwww.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, February 23, 2022 – Orphazyme A/S (ORPHA.CO (DK); ORPH (US)) (the “Company”), a late-stage biopharmaceutical company, today announced an update on the ongoing review of the Marketing Authorisation Application (MAA) for its investigational product candidate, arimoclomol, for the treatment of Niemann-Pick disease type C (NPC) by the Committee for Medicinal Products |
Capital increase of 360,000 shares in Orphazyme A/S as a result of the utilization of the U.S. At-the-Market Offering ProgramOrphazyme A/SCompany announcementNo. 06/2022www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, February 18, 2022 – Orphazyme A/S (ORPHA.CO (DK); ORPH (US)) (the “Company”), a late-stage biopharmaceutical company, announces that the Company has issued new shares in the period from Friday, February 11, 2022 to Thursday, February 17, 2022 as a result of the utilization of the Company’s U.S. At-the-Market Offering Program with Cowen and Company, LLC (“Cowen”). On February 11, 20 |
Resolutions passed at the Extraordinary General MeetingOrphazyme A/SCompany announcementNo. 05/2022www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, February 15, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today held an Extraordinary General Meeting, at which the general meeting: Approved the authorizations to the Board of Directors and amendments to the articles of |
Amendment of proposals put forward at the Extraordinary General MeetingOrphazyme A/SCompany announcementNo. 04/2022 www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, February 14, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announced that the Board of Directors has decided to limit the scope of the proposed authorizations set forward under items 1.2, 1.3 and 1.4 of the agenda o |
Orphazyme (ORPH) Up on Plans of NDA Resubmission for Rare DrugOrphazyme (ORPH) is looking to resubmit its NDA for arimoclomol to the FDA for the treatment of Niemann-Pick disease type C in the United States. Shares rise. |
ORPH Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | -91.23% |
| 5-year | N/A |
| YTD | N/A |
| 2023 | N/A |
| 2022 | 0.00% |
| 2021 | -77.54% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...